GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shockwave Medical Inc (NAS:SWAV) » Definitions » Return-on-Tangible-Equity

Shockwave Medical (Shockwave Medical) Return-on-Tangible-Equity : 38.29% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shockwave Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Shockwave Medical's annualized net income for the quarter that ended in Mar. 2024 was $221.4 Mil. Shockwave Medical's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $578.2 Mil. Therefore, Shockwave Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 38.29%.

The historical rank and industry rank for Shockwave Medical's Return-on-Tangible-Equity or its related term are showing as below:

SWAV' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -145.89   Med: -3.91   Max: 57.36
Current: 30.53

During the past 7 years, Shockwave Medical's highest Return-on-Tangible-Equity was 57.36%. The lowest was -145.89%. And the median was -3.91%.

SWAV's Return-on-Tangible-Equity is ranked better than
90.39% of 760 companies
in the Medical Devices & Instruments industry
Industry Median: 1.32 vs SWAV: 30.53

Shockwave Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Shockwave Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shockwave Medical Return-on-Tangible-Equity Chart

Shockwave Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial -145.89 -31.41 -3.91 57.36 28.12

Shockwave Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.93 21.92 29.46 35.31 38.29

Competitive Comparison of Shockwave Medical's Return-on-Tangible-Equity

For the Medical Devices subindustry, Shockwave Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shockwave Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shockwave Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Shockwave Medical's Return-on-Tangible-Equity falls into.



Shockwave Medical Return-on-Tangible-Equity Calculation

Shockwave Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=147.278/( (511.316+536.252 )/ 2 )
=147.278/523.784
=28.12 %

Shockwave Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=221.384/( (536.252+620.229)/ 2 )
=221.384/578.2405
=38.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Shockwave Medical  (NAS:SWAV) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Shockwave Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Shockwave Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shockwave Medical (Shockwave Medical) Business Description

Traded in Other Exchanges
Address
5403 Betsy Ross Drive, Santa Clara, CA, USA, 95054
ShockWave Medical Inc is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States, Europe and other countries.
Executives
Douglas Evan Godshall director, officer: President & CEO SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Frank T Watkins director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Isaac Zacharias officer: Chief Commercial Officer 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Dan Puckett officer: CFO & Secretary 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Trinh Phung officer: VP, Finance C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Laura Francis director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Sara Toyloy director C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Antoine Papiernik director, 10 percent owner 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Sofinnova Capital Vii Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 18 RUE DU 4 SEPTEMBRE, 75002 PARIS I0 00000
Cahill Colin director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105